HR and acute myeloid leukemia: High estrogen receptor signaling separated hormone receptor (HR)-driven BRCAs from all other tumors (Fig. 1D), while high inflammation characterized tumors with known immunologic involvement, including SKCM, Epstein–Barr virus positive STES, immunoreactive OV, THYM, and acute myeloid leukemia (LAML; Fig. 1F).